- Home
- Your Messages
-
Smartest Doc
Test your clinical knowledge against other physicians in the USA by taking our FREE daily quiz!
No quiz today.
Current Top Players:
1) Dr. Sandeep Chunduri
2) Dr. Hassan Ghazal
3) Dr. Hemang Dave
>> Live LeaderboardNew! PHYSICIAN REVIEW
Assess your general knowledge at the topic level with your personalized scorecard.
Thousands of multiple-choice questions pinpoint your areas of expertise and prep you for exams.
- Physician Jobs (512)
- More
- Other Specialty
Oncology News & Articles
Looking for the latest in oncology clinical literature? You've found the right page. MDLinx Oncology medical editors comb through the top peer-reviewed clinical journals for the articles they think will make a difference to you and your practice. You'll find them organized here by topic including breast, hematologic, thoracic, gastrointestinal and genitourinary cancers. In a matter of minutes, oncologists, oncology nurses, physician assistants and the whole cancer care team can stay current on the literature as it is published.
On this page, you'll also find MDLinx exclusive content, including monthly highlights from our physician editor, D. Scott Cunningham, MD, PhD. We feature clinical pearls as well, from The Smartest Oncologist to oncology topics in The Smartest Pediatrician daily quiz challenges.
Your Unread Messages in Oncology
See All >> Messages include industry-sponsored communications and special communications from MDLinx-
D Scott Cunningham MD, PhD
Site Editor, MDLinx
Markers of obesity and inflammation in postmenopausal breast cancer -
Jill Baker
MDLinx Career Center
NPs and PAs play crucial role amid PCP shortage -
Smartest Doc Challenge
MDLinx
Melanoma Clinical Pearls -
MDLinx Reminder
MDLinx
Conference Center Upgraded with New Tools -
MDLinx Top Read
MDLinx
Running from that pile of unread journals?
Articles
Latest (118) Full Text Articles (6313) Focus on Bone321 IL-12 selectively programs effector pathways that are stably expressed in human CD8+ effector memory T cells in vivo Full Text Blood, September 2, 2012 Original Publication Date: September 1, 2011
322 microRNA-Associated Progression Pathways and Potential Therapeutic Targets Identified by Integrated mRNA and microRNA Expression Profiling in Breast Cancer Full Text Cancer Research, September 2, 2012 Original Publication Date: September 2, 2011
323 Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia Full Text Blood, September 1, 2012 Original Publication Date: September 1, 2011
324 Dicer-Mediated Upregulation of BCRP Confers Tamoxifen Resistance in Human Breast Cancer Cells Full Text Clinical Cancer Research, September 1, 2012 Original Publication Date: September 1, 2011 Clinical Article
325 Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor-positive Locally Advanced or Metastatic Breast Cancer Full Text Clinical Cancer Research, September 1, 2012 Original Publication Date: September 1, 2011
326 Menopausal Hormone Therapy and Risks of Melanoma and Nonmelanoma Skin Cancers: Women’s Health Initiative Randomized Trials Full Text Journal of the National Cancer Institute, September 1, 2012 Original Publication Date: September 1, 2011
327 PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients Full Text Clinical Cancer Research, September 1, 2012 Original Publication Date: September 1, 2011
328 Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer Full Text Annals of Oncology, September 1, 2012 Original Publication Date: September 1, 2011
329 Dietary fat and breast cancer: comparison of results from food diaries and food-frequency questionnaires in the UK Dietary Cohort Consortium Full Text American Journal of Clinical Nutrition, September 1, 2012 Original Publication Date: September 1, 2011
330 How I treat patients who mobilize hematopoietic stem cells poorly Full Text Blood, September 1, 2012 Original Publication Date: August 31, 2011
331 Tetraspanin CD151 maintains vascular stability by balancing the forces of cell adhesion and cytoskeletal tension Full Text Blood, September 1, 2012 Original Publication Date: August 31, 2011
332 Vascular endothelial growth factor-induced elimination of type 1 interferon receptor is required for efficient angiogenesis Full Text Blood, September 1, 2012 Original Publication Date: August 31, 2011
333 Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud? Full Text Cancer Management and Research, August 31, 2012 Clinical Article
334 Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer Full Text BMC Cancer, August 31, 2012
335 The value of perioperative mitomycin c instillation in improving subsequent bacillus calmette-guerin instillation efficacy in intermediate and high-risk patients with non-muscle invasive bladder cancer: a prospective randomized study Full Text International Braz J Urol, August 31, 2012 Clinical Article
336 PCA3 Score and Prostate Cancer Diagnosis at Repeated Saturation Biopsy. Which cut-off: 20 or 35 Full Text International Braz J Urol, August 31, 2012 Clinical Article
337 Immunohistochemical expression of CD44s in renal cell carcinoma lacks independent prognostic significance Full Text International Braz J Urol, August 31, 2012
338 The T-box transcription factor Brachyury regulates epithelial-mesenchymal transition in association with cancer stem-like cells in adenoid cystic carcinoma cells Full Text BMC Cancer, August 31, 2012
339 The molecular profile of luminal B breast cancer Full Text Biologics: targets & therapy, August 31, 2012
340 The prevalence of prostate cancer in Brazil is higher in Black men than in White men: systematic review and meta-analysis Full Text International Braz J Urol, August 31, 2012 Evidence Based Medicine
Clinical Pearls in Oncology
- The ZORO study demonstrated that the addition of goserelin to neoadjuvant chemotherapy for early breast cancer in premenopausal women resulted in no change in post-chemotherapy rates of amenorrhea
- A little over 50% of tumors in women with ER-positive, node-negative breast cancers will have a RS <18, and current data suggests that these women are UNLIKELY to receive a benefit from adjuvant chemotherapy
- In patients with completely resected ER-positive DCIS when the surgical specimen also has LCIS, consider breast MRI screening in addition to mammography due to the lower sensitivity of mammograms for lobular disease
Highlights in Oncology
VEGFR-1 is a prognostic marker for HCC
As reported in the Journal of Pathology, the expression of vascular endothelial growth factor receptor (VEGFR)-1 is elevated in invasive hepatocellular cancer (HCC) specimens. In a study based on 135 HCC specimens, elevated VEGFR-1 was also associated with worse recurrence-free and overall survival.
Read the article summaryHCC risk increased in patients with AIDS
As reported in Cancer, researchers from the NCI have reported that patients with AIDS have a 4-fold increased risk of HCC compared to the general population. The study findings were based on 615,150 patients with AIDS between 1980 and 2009. The risk for HCC in patients with AIDS was essentially the same during the monotherapy/dual therapy and highly active anti-retroviral therapy eras.
Read the article summaryRAB25 is a prognostic marker for ovarian cancer
As reported in the International Journal of Cancer Research and Treatment, the pre-operative level of RAB25 is a predictor of disease-free survival (HR=18.2) and overall survival (HR=33.6) in patients with ovarian cancer. The study involved 36 and 16 women with ovarian cancer and benign tumors, respectively. The pre-operative cell-free DNA of genes (B2M, RAB25, CLDN4, and ABCF2) were measured and RAB25 was shown to be an independent prognostic factor.
Read the article summaryMost Popular Oncology Articles
Last month's top read Top Articles of 20121 Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial European Journal of Cancer, April 2, 2013
2 R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the FOLL05 Trial conducted by the Fondazione Italiana Linfomi Journal of Clinical Oncology, April 1, 2013
3 Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013 Mayo Clinic Proceedings, April 2, 2013 Clinical Guideline
4 Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study Annals of Oncology, April 3, 2013
5 Phase 2 study of dose-intense temozolomide in recurrent glioblastoma Neuro-Oncology, April 9, 2013
6 Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study Journal of the National Cancer Institute, April 4, 2013
7 Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments BMC Cancer, April 3, 2013 Free full text
8 Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27--A Randomized Controlled Phase III Trial Journal of Clinical Oncology, February 11, 2013
9 Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial The Lancet Oncology, March 12, 2013
10 Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study Annals of Oncology, April 1, 2013
11 High pretreatment serum lactate dehydrogenase level correlates with disease relapse and predicts an inferior outcome in locally advanced nasopharyngeal carcinoma European Journal of Cancer, April 5, 2013
12 Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial The Lancet Oncology, April 12, 2013
13 Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202) Journal of Clinical Oncology, April 15, 2013
14 Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: Patterns of failure and prognostic factors Cancer, April 11, 2013
15 Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer Cancer, April 10, 2013
16 Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial The Lancet Oncology, February 15, 2013
17 Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)±bevacizumab: Results of the randomised GeparQuinto study (GBG 44) European Journal of Cancer, April 5, 2013
18 Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial Annals of Oncology, April 4, 2013
19 Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) Annals of Oncology, April 16, 2013
20 R-CHOP therapy alone in limited stage diffuse large B-cell lymphoma British Journal of Haematology, March 1, 2013
Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncology more
Other Topics in Oncology
Register now to view all the MDLinx contents (FREE)!
- Stay current on the latest literature, research and clinical news
- Get special communications and offers from MDLinx and our sponsors
- Receive invitations to paid market research
Login
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close